Decisions of the extraordinary shareholders meeting of Brighter AB.

Brighter AB (publ), reg. no. 556736-8591, has held an extraordinary shareholders meeting on Friday the 29th of September 2017 regarding the warrant programs.

The shareholders meeting decided to approve the Remuneration Committee’s proposal regarding item 7 (Resolution on the extension of the warrant program Series I 2014/2017) and item 8 (Resolution on the extension of the warrant program Series II 2014/2017).

Furthermore, the shareholders meeting decided to approve the Remuneration Committee’s proposal regarding item 9 (Resolution on the issuance of warrants, as well as the approval of the transfer of warrants to the company’s Board members Series I 2017/2020 – Series I 2017/2020) with adjusted Black & Scholes calculation period from 31 August to 27 September, with a subscription price per share at SEK 22,62.

Regarding item 10 (Resolution on the issuance of warrants, as well as the approval of the transfer of warrants to employees and key members of the company – Series II 2017/2020) the shareholders meeting decided to approve the Remuneration Committee’s proposal with adjusted Black & Scholes calculation period from 31 August to 27 September, with a subscription price per share at SEK 22,62.

All decisions were unanimous except for reservation by Sveriges Aktiesparares Riksförbund (the Swedish Shareholders' Association).

For more information, please contact:

Truls Sjöstedt, CEO   
Tel: +46 709 73 46 00   
Email: truls.sjostedt@brighter.se

Henrik Norström, COO   
Tel: +46 733 40 30 45   
Email: henrik.norstrom@brighter.se

About Brighter AB (publ)   
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.

About Us

Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first innovative tool Actiste®, the company creates a more efficient care chain with focus on the individual. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

Subscribe

Documents & Links